Show simple item record

dc.contributor.authorBevan-Jones, Richard W
dc.contributor.authorCope, Thomas
dc.contributor.authorJones, Simon
dc.contributor.authorPassamonti, Luca
dc.contributor.authorHong, Young
dc.contributor.authorFryer, Timothy
dc.contributor.authorArnold, Robert
dc.contributor.authorColes, Jonathan
dc.contributor.authorAigbirhio, Franklin A
dc.contributor.authorPatterson, Karalyn
dc.contributor.authorO'Brien, John
dc.contributor.authorRowe, James
dc.date.accessioned2018-11-30T00:32:24Z
dc.date.available2018-11-30T00:32:24Z
dc.date.issued2018-10
dc.identifier.issn2328-9503
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/286142
dc.description.abstractThe PET ligand [18F]AV-1451 was developed to bind tau pathology in Alzheimer's disease, but increased binding has been shown in both genetic tauopathies and in semantic dementia, a disease strongly associated with TDP-43 pathology. Here we assessed [18F]AV-1451 binding in behavioral variant frontotemporal dementia due to a hexanucleotide repeat expansion in C9orf72, characterized by TDP-43 pathology. We show that the C9orf72 mutation increases binding in frontotemporal cortex, with a distinctive distribution of binding compared with healthy controls.
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.publisherWiley
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.title[18F]AV-1451 binding is increased in frontotemporal dementia due to C9orf72 expansion.
dc.typeArticle
prism.endingPage1296
prism.issueIdentifier10
prism.publicationDate2018
prism.publicationNameAnn Clin Transl Neurol
prism.startingPage1292
prism.volume5
dc.identifier.doi10.17863/CAM.33456
dc.identifier.doi10.17863/CAM.33456
dcterms.dateAccepted2018-07-20
rioxxterms.versionofrecord10.1002/acn3.631
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-10
dc.contributor.orcidCope, Thomas [0000-0002-4751-1786]
dc.contributor.orcidJones, Simon [0000-0001-9695-0702]
dc.contributor.orcidPassamonti, Luca [0000-0002-7937-0615]
dc.contributor.orcidColes, Jonathan [0000-0003-4013-679X]
dc.contributor.orcidPatterson, Karalyn [0000-0003-1927-7424]
dc.contributor.orcidO'Brien, John [0000-0002-0837-5080]
dc.contributor.orcidRowe, James [0000-0001-7216-8679]
dc.identifier.eissn2328-9503
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
pubs.funder-project-idNational Institute for Health Research (NIHR) (via Cambridgeshire and Peterborough NHS Foundation Trust (CPFT) (DTC-RP-PG-0311-12001)
pubs.funder-project-idWellcome Trust (103838/Z/14/Z)
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (unknown)
pubs.funder-project-idMedical Research Council (MR/P01271X/1)
pubs.funder-project-idMedical Research Council (MR/K02308X/1)
pubs.funder-project-idEngineering and Physical Sciences Research Council (EP/P008224/1)
pubs.funder-project-idMedical Research Council (MR/M009041/1)
pubs.funder-project-idMedical Research Council (MC_U105597119)
pubs.funder-project-idMedical Research Council (MR/M024873/1)
pubs.funder-project-idMedical Research Council (MC_UU_00005/12)
cam.issuedOnline2018-09-14


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International